<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03114995</url>
  </required_header>
  <id_info>
    <org_study_id>B-1111-140-001</org_study_id>
    <nct_id>NCT03114995</nct_id>
  </id_info>
  <brief_title>Tailored Use of Tirofiban for Non-ST-elevation Acute Coronary Syndrome Patients</brief_title>
  <official_title>Effect of Tailored Use of Tirofiban in Patients With Non-ST-elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Bundang Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Bundang Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigators aimed to test the beneficial effect of tirofiban, a GPIIb/IIIa antagonist, for
      Non-ST-Elevation Acute Coronary Syndrome Patients who has high resistance to clopidogrel.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Some patients have a poor response to dual antiplatelet therapy (DAPT), and it can result in
      a poor prognosis after percutaneous coronary intervention (PCI). Devices like Ultegra Rapid
      Platelet Function Analyzer (VerifyNow®) enable us to quantify platelet reactivity quickly in
      the catheter laboratory. This means that the poor responders to DAPT can be identified, and
      the patients' outcomes can be improved by providing additional antiplatelet agents.
      Tirofiban, a GP IIb/IIIa inhibitor, is a potent antiplatelet agent which is recommended for
      Non-ST-Elevation acute coronary syndrome (NSTE-ACS) with high risk at presentation. However,
      its role is not clear for patients stabilized with standard medical treatment but with a poor
      responsiveness to DAPT.

      In this study, Investigators administered tirofiban on top of DAPT to patients with NSTE-ACS
      undergoing PCI who have a high platelet reactivity (HPR) identified by VerifyNow.

      To the best of our knowledge, there are few studies conducted with tirofiban for tailored
      antiplatelet therapy. Moreover, this is the first randomized study with NSTE-ACS patients for
      tailored use of tirofiban under the guidance of platelet reactivity.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 1, 2012</start_date>
  <completion_date type="Actual">October 1, 2015</completion_date>
  <primary_completion_date type="Actual">October 1, 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under Curve of Serial Cardiac Biomarkers</measure>
    <time_frame>0,6,12,18,24,30,36 hours</time_frame>
    <description>An area under the curve of serial levels of Troponin I and creatine kinase-MB isoenzyme during 36 hours</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Periprocedural Myonecrosis</measure>
    <time_frame>0,6,12,18,24,30,36 hours</time_frame>
    <description>Percentage of participants with periprocedural myonecrosis under the criteria described below.
When the cardiac biomarkers before the procedure were within the 99th percentile upper reference limit (URL), more than a 5-fold elevation in the URL within 12 hours after percutaneous coronary intervention (PCI) was defined as periprocedural myonecrosis. If the cardiac biomarker level was already above the 99th percentile URL before the procedure and the trend was stationary or decreasing, a ≥20% increase compared to the previous level was considered periprocedural myonecrosis. If the trend was still increasing, the levels at the post-6 hour and 12-hour were compared to determine periprocedural myonecrosis.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">140</enrollment>
  <condition>Non-ST Elevation Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Group A (high platelet reactivity - tirofiban)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with high platelet reactivity unit (230 or higher) Tirofiban administered dose: 0.4 μg/kg/min continuous infusion for 30 min and then 0.10 μg/kg/min continuous infusion for 12 h</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control C1 (high platelet reactivity - no tirofiban)</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients with high platelet reactivity unit (230 or higher) Tirofiban was not administered</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control C2 (low platelet reactivity - no tirofiban)</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients with low platelet reactivity unit (less than 230) Tirofiban was not administered</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tirofiban</intervention_name>
    <arm_group_label>Group A (high platelet reactivity - tirofiban)</arm_group_label>
    <other_name>Agrastat</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  diagnosed with NSTE-ACS who need PCI

          -  loaded with aspirin and clopidogrel at least 6 h before the procedure

        Exclusion Criteria:

          -  thrombocytopenia (platelet count &lt;100,000/μL)

          -  history of hemorrhagic stroke

          -  history of ischemic stroke in the recent 2 year

          -  history of major surgery 6 months prior
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tae-Jin Youn, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Bundang Hospital</affiliation>
  </overall_official>
  <results_reference>
    <citation>Patti G, Nusca A, Mangiacapra F, Gatto L, D'Ambrosio A, Di Sciascio G. Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention results of the ARMYDA-PRO (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity Predicts Outcome) study. J Am Coll Cardiol. 2008 Sep 30;52(14):1128-33. doi: 10.1016/j.jacc.2008.06.038.</citation>
    <PMID>18804738</PMID>
  </results_reference>
  <results_reference>
    <citation>Hong MK, Mehran R, Dangas G, Mintz GS, Lansky AJ, Pichard AD, Kent KM, Satler LF, Stone GW, Leon MB. Creatine kinase-MB enzyme elevation following successful saphenous vein graft intervention is associated with late mortality. Circulation. 1999 Dec 14;100(24):2400-5.</citation>
    <PMID>10595951</PMID>
  </results_reference>
  <results_reference>
    <citation>Fung AY, Saw J, Starovoytov A, Densem C, Jokhi P, Walsh SJ, Fox RS, Humphries KH, Aymong E, Ricci DR, Webb JG, Hamburger JN, Carere RG, Buller CE. Abbreviated infusion of eptifibatide after successful coronary intervention The BRIEF-PCI (Brief Infusion of Eptifibatide Following Percutaneous Coronary Intervention) randomized trial. J Am Coll Cardiol. 2009 Mar 10;53(10):837-45. doi: 10.1016/j.jacc.2008.09.060.</citation>
    <PMID>19264239</PMID>
  </results_reference>
  <results_reference>
    <citation>De Labriolle A, Lemesle G, Bonello L, Syed AI, Collins SD, Ben-Dor I, Pinto Slottow TL, Xue Z, Torguson R, Suddath WO, Satler LF, Kent KM, Pichard AD, Lindsay J, Waksman R. Prognostic significance of small troponin I rise after a successful elective percutaneous coronary intervention of a native artery. Am J Cardiol. 2009 Mar 1;103(5):639-45. doi: 10.1016/j.amjcard.2008.10.044. Epub 2009 Jan 17.</citation>
    <PMID>19231326</PMID>
  </results_reference>
  <results_reference>
    <citation>Jeremias A, Kleiman NS, Nassif D, Hsieh WH, Pencina M, Maresh K, Parikh M, Cutlip DE, Waksman R, Goldberg S, Berger PB, Cohen DJ; Evaluation of Drug Eluting Stents and Ischemic Events (EVENT) Registry Investigators. Prevalence and prognostic significance of preprocedural cardiac troponin elevation among patients with stable coronary artery disease undergoing percutaneous coronary intervention: results from the evaluation of drug eluting stents and ischemic events registry. Circulation. 2008 Aug 5;118(6):632-8. doi: 10.1161/CIRCULATIONAHA.107.752428. Epub 2008 Jul 21.</citation>
    <PMID>18645057</PMID>
  </results_reference>
  <results_reference>
    <citation>Cuisset T, Hamilos M, Sarma J, Sarno G, Wyffels E, Vanderheyden M, Barbato E, Bartunek J, De Bruyne B, Wijns W. Relation of low response to clopidogrel assessed with point-of-care assay to periprocedural myonecrosis in patients undergoing elective coronary stenting for stable angina pectoris. Am J Cardiol. 2008 Jun 15;101(12):1700-3. doi: 10.1016/j.amjcard.2008.02.054. Epub 2008 Apr 18.</citation>
    <PMID>18549843</PMID>
  </results_reference>
  <results_reference>
    <citation>Suh JW, Lee SP, Park KW, Lee HY, Kang HJ, Koo BK, Cho YS, Youn TJ, Chae IH, Choi DJ, Rha SW, Bae JH, Kwon TG, Bae JW, Cho MC, Kim HS. Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: results of the CILON-T (influence of CILostazol-based triple antiplatelet therapy ON ischemic complication after drug-eluting stenT implantation) trial. J Am Coll Cardiol. 2011 Jan 18;57(3):280-9. doi: 10.1016/j.jacc.2010.08.631.</citation>
    <PMID>21232664</PMID>
  </results_reference>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>April 11, 2017</study_first_submitted>
  <study_first_submitted_qc>April 11, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 14, 2017</study_first_posted>
  <results_first_submitted>May 8, 2018</results_first_submitted>
  <results_first_submitted_qc>May 8, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">June 8, 2018</results_first_posted>
  <last_update_submitted>June 18, 2018</last_update_submitted>
  <last_update_submitted_qc>June 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Bundang Hospital</investigator_affiliation>
    <investigator_full_name>Tae-Jin Youn</investigator_full_name>
    <investigator_title>Professor, Cardiovascular Center</investigator_title>
  </responsible_party>
  <keyword>Tirofiban</keyword>
  <keyword>Resistance to antiplatelet agents</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
    <mesh_term>Non-ST Elevated Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tirofiban</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>not planned</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Consecutively enrolled patients who are already stabilized with standard medical treatment and diagnosed with Non-ST elevation acute coronary syndrome (NSTE-ACS) at Seoul National University Bundang Hospital from February 2012 to October 2015</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Group A (High Platelet Reactivity - Tirofiban)</title>
          <description>Patients with high platelet reactivity (HPR) unit (230 or higher) Tirofiban administered dose: 0.4 μg/kg/min continuous infusion for 30 min and then 0.10 μg/kg/min continuous infusion for 12 h
Tirofiban</description>
        </group>
        <group group_id="P2">
          <title>Control C1 (High Platelet Reactivity - no Tirofiban)</title>
          <description>Patients with high platelet reactivity unit (230 or higher) Tirofiban was not administered</description>
        </group>
        <group group_id="P3">
          <title>Control C2(Low Platelet Reactivity - no Tirofiban)</title>
          <description>Patients with low platelet reactivity unit (less than 230) Tirofiban was not administered</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="31"/>
                <participants group_id="P3" count="78"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="30"/>
                <participants group_id="P3" count="78"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group A (High Platelet Reactivity - Tirofiban)</title>
          <description>Patients with high platelet reactivity unit (230 or higher) Tirofiban administered dose: 0.4 μg/kg/min continuous infusion for 30 min and then 0.10 μg/kg/min continuous infusion for 12 h
Tirofiban</description>
        </group>
        <group group_id="B2">
          <title>Control C1 (High Platelet Reactivity - no Tirofiban)</title>
          <description>Patients with high platelet reactivity unit (230 or higher) Tirofiban was not administered</description>
        </group>
        <group group_id="B3">
          <title>Control C2 (Low Platelet Reactivity - no Tirofiban)</title>
          <description>Patients with low platelet reactivity unit (less than 230) Tirofiban was not administered</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
            <count group_id="B2" value="30"/>
            <count group_id="B3" value="78"/>
            <count group_id="B4" value="138"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70.0" spread="12.8"/>
                    <measurement group_id="B2" value="64.5" spread="12.0"/>
                    <measurement group_id="B3" value="62.9" spread="10.1"/>
                    <measurement group_id="B4" value="64.8" spread="11.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="67"/>
                    <measurement group_id="B4" value="109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Area Under Curve of Serial Cardiac Biomarkers</title>
        <description>An area under the curve of serial levels of Troponin I and creatine kinase-MB isoenzyme during 36 hours</description>
        <time_frame>0,6,12,18,24,30,36 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group A (High Platelet Reactivity - Tirofiban)</title>
            <description>Patients with high platelet reactivity unit (230 or higher) Tirofiban administered dose: 0.4 μg/kg/min continuous infusion for 30 min and then 0.10 μg/kg/min continuous infusion for 12 h
Tirofiban</description>
          </group>
          <group group_id="O2">
            <title>Control C1 (High Platelet Reactivity - no Tirofiban)</title>
            <description>Patients with high platelet reactivity unit (230 or higher) Tirofiban was not administered</description>
          </group>
          <group group_id="O3">
            <title>Control C2 (Low Platelet Reactivity - no Tirofiban)</title>
            <description>Patients with low platelet reactivity unit (less than 230) Tirofiban was not administered</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under Curve of Serial Cardiac Biomarkers</title>
          <description>An area under the curve of serial levels of Troponin I and creatine kinase-MB isoenzyme during 36 hours</description>
          <units>Hours*ng/ml</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Troponin I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="197.2" lower_limit="41.5" upper_limit="395.7"/>
                    <measurement group_id="O2" value="38.0" lower_limit="8.9" upper_limit="313.9"/>
                    <measurement group_id="O3" value="121.4" lower_limit="43.7" upper_limit="481.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>creatine kinase-MB isoenzyme</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="252.5" lower_limit="48.0" upper_limit="470.1"/>
                    <measurement group_id="O2" value="92.7" lower_limit="39.1" upper_limit="402.1"/>
                    <measurement group_id="O3" value="185.6" lower_limit="79.8" upper_limit="425.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Periprocedural Myonecrosis</title>
        <description>Percentage of participants with periprocedural myonecrosis under the criteria described below.
When the cardiac biomarkers before the procedure were within the 99th percentile upper reference limit (URL), more than a 5-fold elevation in the URL within 12 hours after percutaneous coronary intervention (PCI) was defined as periprocedural myonecrosis. If the cardiac biomarker level was already above the 99th percentile URL before the procedure and the trend was stationary or decreasing, a ≥20% increase compared to the previous level was considered periprocedural myonecrosis. If the trend was still increasing, the levels at the post-6 hour and 12-hour were compared to determine periprocedural myonecrosis.</description>
        <time_frame>0,6,12,18,24,30,36 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group A (High Platelet Reactivity - Tirofiban)</title>
            <description>Patients with high platelet reactivity unit (230 or higher) Tirofiban administered dose: 0.4 μg/kg/min continuous infusion for 30 min and then 0.10 μg/kg/min continuous infusion for 12 h
Tirofiban</description>
          </group>
          <group group_id="O2">
            <title>Control C1 (High Platelet Reactivity - no Tirofiban)</title>
            <description>Patients with high platelet reactivity unit (230 or higher) Tirofiban was not administered</description>
          </group>
          <group group_id="O3">
            <title>Control C2 (Low Platelet Reactivity - no Tirofiban)</title>
            <description>Patients with low platelet reactivity unit (less than 230) Tirofiban was not administered</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Periprocedural Myonecrosis</title>
          <description>Percentage of participants with periprocedural myonecrosis under the criteria described below.
When the cardiac biomarkers before the procedure were within the 99th percentile upper reference limit (URL), more than a 5-fold elevation in the URL within 12 hours after percutaneous coronary intervention (PCI) was defined as periprocedural myonecrosis. If the cardiac biomarker level was already above the 99th percentile URL before the procedure and the trend was stationary or decreasing, a ≥20% increase compared to the previous level was considered periprocedural myonecrosis. If the trend was still increasing, the levels at the post-6 hour and 12-hour were compared to determine periprocedural myonecrosis.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Troponin I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>creatine kinase-MB isoenzyme</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 month</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Group A (High Platelet Reactivity - Tirofiban)</title>
          <description>Patients with high platelet reactivity unit (230 or higher) Tirofiban administered dose: 0.4 μg/kg/min continuous infusion for 30 min and then 0.10 μg/kg/min continuous infusion for 12 h
Tirofiban</description>
        </group>
        <group group_id="E2">
          <title>Control C1 (High Platelet Reactivity - no Tirofiban)</title>
          <description>Patients with high platelet reactivity unit (230 or higher) Tirofiban was not administered</description>
        </group>
        <group group_id="E3">
          <title>Control C2 (Low Platelet Reactivity - no Tirofiban)</title>
          <description>Patients with low platelet reactivity unit (less than 230) Tirofiban was not administered</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Minor bleeding</sub_title>
                <description>Minor bleeding defined by TIMI criteria</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The difference in the distribution of PRU values of subjects estimated from previous literatures leading to small numbers of subjects assigned to the study group</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Tae-Jin Youn</name_or_title>
      <organization>Cardiovascular Center, Seoul National University Bundang Hospital</organization>
      <phone>+82-31-787-7031</phone>
      <email>ytjmd@snubh.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

